Response to letter to editor on the article: Ge W, Chen C-I, Wu N <i>et al.</i> Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. <i>Fut. Oncol.</i> 18(23), 2561

Response to letter to editor on the article: Ge W, Chen C-I, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. Fut. Oncol. 18(23), 2561–2572 (2022)

Published:2023-11-14 Issue: Volume: Page:
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Ge Wenzhen¹,Chen Chieh-I¹,Wu Ning¹,Fury Matthew G¹,Ruiz Emily²,Jalbert Jessica J³

Affiliation:

1. Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA

2. Brigham & Women's Hospital, Harvard Medical School – Department of Dermatology, 450 Brookline Ave, Boston, MA 02215, USA

3. Regeneron Pharmaceuticals, Inc., HEOR, 1 Rockwood Road, Sleepy Hollow, NY 10591, USA

Funder

Regeneron Pharmaceuticals

Sanofi

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2023-0837

Reference9 articles.

1. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis

2. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial

3. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

4. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study

5. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial